Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000401701

Medchemexpress LLC ABT-639 | 1235560-28-7 | 99.3% | 455.91 | 50 MG
SDP

Catalog No. 5000401701
Encompass_Preferred

ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. It is used for research purposes only and not sold to patients. It effectively reduces nociceptive and neuropathic pain in rats.

  • Blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion.
  • Attenuates low voltage-activated (LVA) currents in rat DRG neurons.
  • Significantly less active at other Ca2+ channels (e.g., Cav1.2 and Cav2.2).
  • High oral bioavailability (%f=73) in rodents.
  • Low protein binding (88.9%) in rodents.
  • Low brain:plasma ratio (0.05:1) in rodents.
  • Produces dose-dependent antinociception in a rat model of knee joint pain.
  • Increases tactile allodynia thresholds in multiple models of neuropathic pain.
  • Does not significantly alter hemodynamic or psychomotor function at higher doses.

Catalog No. 50-004-01701 Supplier Medchemexpress LLC Supplier No. HY1972150MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. It is used for research purposes only and not sold to patients. It effectively reduces nociceptive and neuropathic pain in rats.

  • Blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion.
  • Attenuates low voltage-activated (LVA) currents in rat DRG neurons.
  • Significantly less active at other Ca2+ channels (e.g., Cav1.2 and Cav2.2).
  • High oral bioavailability (%f=73) in rodents.
  • Low protein binding (88.9%) in rodents.
  • Low brain:plasma ratio (0.05:1) in rodents.
  • Produces dose-dependent antinociception in a rat model of knee joint pain.
  • Increases tactile allodynia thresholds in multiple models of neuropathic pain.
  • Does not significantly alter hemodynamic or psychomotor function at higher doses.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.